COVID-19SurgCOVID-MosNCT07719166
Treatment and Outcomes in Patients With COVID-19 and Competing Acute Surgical Diseases in Moscow
An observational study of COVID-19 and Emergency Surgery, run by Pirogov Russian National Research Medical University at 1 site in Russia.
Trial summary
The COVID-19 pandemic has posed a significant challenge to surgical practice. This study aims to investigate the structure of hospitalizations, treatment outcomes, and surgical tactics in patients with COVID-19 and competing different acute surgical diseases (ASD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19, Emergency Surgery, Abdominal Surgery
- What is being tested?
- Surgical and Interventional Management of Acute Surgical Conditions
- Type of treatment
- Surgery or procedure
- How many people
- 58,000 participants
- Where
- 1 siteRussia
- Study dates
- 1 Mar 2020to 1 Jul 2026
- How long will I take part?
- 4 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study cohort was assembled based on data from the Kommunarka Moscow Multidisciplinary Clinical Center (Moscow)-a facility repurposed to treat patients with COVID-19 alongside concurrent acute emergencies across surgical, cardiological, neurological, trauma, and neurosurgical specialties. It comprises medical data regarding the hospitalization and treatment outcomes of patients treated as inpatients during the pandemic period (March 1, 2020, to March 1, 2022) and the post-pandemic period (January 1, 2023, to December 31, 2024). De-identified data were derived from routine medical records and the hospital's medical information system. The dataset reflects real-world clinical practice in the care of patients with COVID-19 and acute surgical conditions, including abdominal, thrombotic, hemorrhagic, infectious-inflammatory, and other surgically significant pathologies.
Who may be able to join
- Age 18 years or older.
- Hospitalization at the MMCC "Kommunarka".
- A confirmed diagnosis of COVID-19 (based on current clinical guidelines).
- Presence of one or more any acute surgical diseases (ASD) considered competing with COVID-19 or as a complication of COVID-19/its treatment, as per the discharge summary.
- For specific sub-studies: Patients with acute surgical diseases of the abdominal organs.
- For specific sub-studies: Patients with clinically significant spontaneous soft tissue hematomas or pneumomediastinum or other acute surgical diseases.
Who cannot join
- Patients for whom a diagnosis of COVID-19 was not established according to the discharge summary.
- Patients for whom none of the studied acute surgical diseases were established according to the discharge summary.
- Patients who underwent elective surgeries and developed COVID-19 in the postoperative period.
- Patients operated on in another hospital and transferred with suspected COVID-19 (if not confirmed).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Outcomes and Treatment Strategy for Patients With COVID-19 and Concurrent Acute Surgical Conditions: a Single-center Retrospective/Prospective Observational Cohort Study Based on Real-world Data (RWD)
The COVID-19 pandemic has posed a significant challenge to surgical practice. This study aims to investigate the structure of hospitalizations, treatment outcomes, and surgical tactics in patients with COVID-19 and competing different acute surgical diseases (ASD). The research is based on real-world data (RWD) from a large multidisciplinary hospital repurposed as a COVID-19 center. The study analyze the mutual impact of these two acute conditions on patient outcomes, develop prognostic models for in-hospital mortality, and evaluate changes in surgical approaches during the pandemic.
Read the detailed description
This is a single-center, ambidirectional observational cohort study based on routinely collected clinical data from the Moscow Multidisciplinary Clinical Center "Kommunarka," Moscow, Russia. The study evaluates the organization and outcomes of care for patients with acute surgical conditions during two distinct periods of hospital activity: the COVID-19 pandemic period and the post-pandemic period.
The study was designed to address the methodological challenges of analyzing patients with two potentially competing acute conditions: COVID-19 and an acute surgical disease. The clinical spectrum includes acute abdominal diseases, thrombotic and hemorrhagic conditions, soft-tissue infections, thoracic complications, and other conditions requiring surgical assessment or treatment. No diagnostic, surgical, interventional, or medical treatment was assigned or modified by the study protocol. All clinical decisions were made by the treating teams as part of routine care.
Data were obtained from hospital information systems and routine electronic medical records. Source data included demographic characteristics, diagnoses, operative and interventional procedures, selected clinical severity indicators, comorbid conditions, hospitalization dates, discharge status, and other variables required for the planned analyses. The principal unit of analysis was a hospitalization episode rather than an individual data row. Repeated technical records and duplicated entries relating to the same hospitalization were identified and resolved before analysis.
A multistage data-management process was used to transform poorly structured real-world data into clinically interpretable analytical cohorts. The initial screening procedure used diagnostic codes, relevant text fields, procedure information, and predefined clinical terms to identify potentially eligible hospitalization episodes. More specific analytical datasets were subsequently created using stricter diagnostic definitions and clinical review. Certain clinically complex disease groups required manual review of medical records, reassessment of the final diagnosis, clarification of the surgical condition, or verification using imaging and procedural information.
Quality-control procedures included assessment of duplicate records, repeated hospitalizations, inconsistent diagnostic classification, incomplete variables, implausible values, and discrepancies between diagnosis and procedure fields. The process also included review of hospitalizations that may have been incorrectly included or excluded by the initial screening algorithm. Changes to cohort composition, classification rules, and derived variables were documented through versioned datasets and change records. A cohort or dataset passport was used to describe the origin of the data, unit of analysis, cohort-formation rules, level of clinical validation, data limitations, and intended analytical use.
Missing data were not automatically interpreted as absence of the corresponding clinical condition. The amount and pattern of missingness were assessed for relevant variables. Statistical analyses were conducted using the available data for each predefined analytical task. Sensitivity analyses were used where appropriate to assess whether the main findings were affected by alternative cohort definitions, stricter phenotyping rules, or differences in data completeness.
The pandemic and post-pandemic cohorts were analyzed separately and comparatively. The inter-period analysis was intended to assess whether the structure of acute surgical hospitalizations, treatment patterns, and clinical outcomes differed between the specialized pandemic hospital setting and subsequent routine hospital activity. Both broad and more specific cohort definitions were used to evaluate the robustness of the observed differences.
The study also included the development of an organizational and methodological model for conducting research based on real-world data within a medical organization. The model describes the sequence of research activities, distribution of professional roles, clinical validation procedures, data-quality controls, standard operating procedures, dataset documentation, and change management. This component represents a methodological and organizational output of the study and does not constitute an evaluation of the clinical effectiveness of an implemented institutional program.
Because this is a nonrandomized observational study, associations between patient characteristics, treatment strategies, historical periods, and outcomes are interpreted cautiously. Surgical intervention may reflect disease severity, clinical selection, and treatment necessity and is not interpreted as an independently assigned exposure or a proven cause of outcome.
- Conditions
- COVID-19, Emergency Surgery, Abdominal Surgery, Real-World Data
- Being tested
- Surgical and Interventional Management of Acute Surgical Conditions
- Keywords
- SARS-CoV-2, COVID-19, Emergency Surgery, Abdominal Surgery, Real-World Data, Data-management, Mortality, Pandemic
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical and Interventional Management of Acute Surgical ConditionsProcedure or surgery
Surgical and interventional procedures performed as part of routine clinical care for acute surgical conditions, including abdominal, thrombotic, hemorrhagic, infectious, and other surgically significant conditions. Procedures included open and laparoscopic surgery, bowel resection, drainage, debridement, hemostatic procedures, angiography, endovascular embolization, and other condition-specific interventions, as clinically indicated. Treatment was not assigned, standardized, or modified by the study protocol. The type and timing of each procedure and the associated in-hospital and postoperative outcomes were obtained from routine medical records and analyzed across clinical subgroups and the pandemic and post-pandemic periods.
| Study group | Role | What they receive |
|---|---|---|
| Pandemic-Period Acute Surgical Disease Cohort | This cohort includes hospitalizations at the Moscow Multidisciplinary Clinical Center "Kommunarka" from March 1, 2020, to March 1, 2022, in which one or more acute surgical conditions were identified from routine clinical records. The cohort includes hospitalizations with confirmed COVID-19 and hospitalizations without confirmed or probable COVID-19, allowing within-period comparisons by COVID-19 status. No intervention was assigned by the study. Surgical, interventional, or conservative treatment was provided according to routine clinical practice. The cohort was used to assess the structure of acute surgical conditions, in-hospital and postoperative mortality, surgical activity, treatment strategies, and factors associated with adverse outcomes. Receives: Procedure: Surgical and Interventional Management of Acute Surgical Conditions | |
| Post-Pandemic Acute Surgical Disease Cohort | This cohort includes emergency hospitalizations at the Moscow Multidisciplinary Clinical Center "Kommunarka" from January 1, 2023, to December 31, 2024, in which one or more acute surgical conditions were identified from routine clinical records. Elective hospitalizations were excluded from the analytical cohort. No intervention was assigned by the study. Surgical, interventional, or conservative treatment was provided according to routine clinical practice. The cohort was used to assess the structure of hospitalizations, in-hospital and postoperative mortality, and surgical activity, and to compare these outcomes with the corresponding pandemic-period cohort using broad and more specific RWD-based cohort definitions. Receives: Procedure: Surgical and Interventional Management of Acute Surgical Conditions |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-Hospital Mortality
The proportion of patients who died during their hospital stay. Assessed in patients with a primary or secondary diagnosis of COVID-19 in combination with competing acute surgical diseases.
Measured: From the moment of admission to the hospital until the date of discharge from the hospital or death (until the end of hospitalization) for the entire study period from 01 march 2020 to 01 march 2022 (from the date of discharge)
Secondary outcomes (4)
Structure of Morbidity
The proportion of patients hospitalized with COVID-19 and various groups of acute surgical diseases (e.g., acute abdominal, thrombotic, hemorrhagic).
Measured: During the entire study period (from 01 march 2020 to 01 march 2022)
Postoperative Mortality
The proportion of patients who died after undergoing a surgical intervention for an acute surgical disease.
Measured: From the moment of admission to the hospital until the date of discharge from the hospital or death (until the end of hospitalization) for the entire study period from 01 march 2020 to 01 march 2022 (from the date of discharge)
Surgical Tactics and Outcomes for Specific Conditions
Comparison of outcomes (e.g., mortality, complications) for different surgical treatment strategies (e.g., conservative vs. any surgical management) for specific COVID-19-associated conditions like spontaneous hematomas, pneumomediastinum, and diverticulitis.
The number of cases using various surgical approaches in individual subcohorts of patients with various groups of acute surgical diseases, and the number of fatal outcomes depending on the surgical approach used.
Measured: From the moment of admission to the hospital until the date of discharge from the hospital or death (until the end of hospitalization) for the entire study period from 01 march 2020 to 01 march 2022 (from the date of discharge)
Surgical Activity
The proportion of hospitalizations in which a surgical intervention for an acute surgical disease was performed, assessed overall and by acute surgical disease group, COVID-19 status, and study period. Inter-Period Comparison of Hospitalization Structure and Treatment Outcomes for operated patients.
Measured: At hospital discharge for each hospitalization, with period-level summary at the end of each study period (pandemic: from 01 march 2020 to 01 march 2022 ; post-pandemic: from 01 january 2023 to 01 january 2024).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2026
- Study start1 Mar 2020
- Primary completion1 Jan 2024
- Study completion1 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 58,000 participants (actual)
- Target duration
- 4 Years
Sponsor and investigators
- Lead sponsor
- Pirogov Russian National Research Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- Moscow Multidisciplinary Clinical Center "Kommunarka"
- Responsible party
- Principal investigator, Mosin Sergey, Pirogov Russian National Research Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07719166
- Sponsor's protocol ID
- SurgCOVID-Mos
- Acronym
- SurgCOVID-Mos
- Status last verified
- Jul 2026
- First submitted
- 15 Jul 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: in accordance with national requirements for the security and protection of personal data
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes and Treatment Strategy for Patients With COVID-19 and Concurrent Acute Surgical Conditions: a Single-center Retrospective/Prospective Observational Cohort Study Based on Real-world Data (RWD)
- ClinicalTrials.gov ID
- NCT07719166
- Acronym / sponsor ID
- SurgCOVID-Mos / SurgCOVID-Mos
- Conditions
- COVID-19, Emergency Surgery, Abdominal Surgery, Real-World Data
- Keywords
- SARS-CoV-2, COVID-19, Emergency Surgery, Abdominal Surgery, Real-World Data, Data-management, Mortality, Pandemic
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 58,000 participants (actual)
- Lead sponsor
- Pirogov Russian National Research Medical UniversityUniversity, hospital or other
- Collaborators
- Moscow Multidisciplinary Clinical Center "Kommunarka"
- Study start
- 1 Mar 2020 (actual)
- Primary completion
- 1 Jan 2024 (actual)
- Study completion
- 1 Jul 2026 (actual)
- First posted
- 22 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The COVID-19 pandemic has posed a significant challenge to surgical practice. This study aims to investigate the structure of hospitalizations, treatment outcomes, and surgical tactics in patients with COVID-19 and competing different acute surgical diseases (ASD). The research is based on real-world data (RWD) from a large multidisciplinary hospital repurposed as a COVID-19 center. The study analyze the mutual impact of these two acute conditions on patient outcomes, develop prognostic models for in-hospital mortality, and evaluate changes in surgical approaches during the pandemic.
Detailed description
This is a single-center, ambidirectional observational cohort study based on routinely collected clinical data from the Moscow Multidisciplinary Clinical Center "Kommunarka," Moscow, Russia. The study evaluates the organization and outcomes of care for patients with acute surgical conditions during two distinct periods of hospital activity: the COVID-19 pandemic period and the post-pandemic period.
The study was designed to address the methodological challenges of analyzing patients with two potentially competing acute conditions: COVID-19 and an acute surgical disease. The clinical spectrum includes acute abdominal diseases, thrombotic and hemorrhagic conditions, soft-tissue infections, thoracic complications, and other conditions requiring surgical assessment or treatment. No diagnostic, surgical, interventional, or medical treatment was assigned or modified by the study protocol. All clinical decisions were made by the treating teams as part of routine care.
Data were obtained from hospital information systems and routine electronic medical records. Source data included demographic characteristics, diagnoses, operative and interventional procedures, selected clinical severity indicators, comorbid conditions, hospitalization dates, discharge status, and other variables required for the planned analyses. The principal unit of analysis was a hospitalization episode rather than an individual data row. Repeated technical records and duplicated entries relating to the same hospitalization were identified and resolved before analysis.
A multistage data-management process was used to transform poorly structured real-world data into clinically interpretable analytical cohorts. The initial screening procedure used diagnostic codes, relevant text fields, procedure information, and predefined clinical terms to identify potentially eligible hospitalization episodes. More specific analytical datasets were subsequently created using stricter diagnostic definitions and clinical review. Certain clinically complex disease groups required manual review of medical records, reassessment of the final diagnosis, clarification of the surgical condition, or verification using imaging and procedural information.
Quality-control procedures included assessment of duplicate records, repeated hospitalizations, inconsistent diagnostic classification, incomplete variables, implausible values, and discrepancies between diagnosis and procedure fields. The process also included review of hospitalizations that may have been incorrectly included or excluded by the initial screening algorithm. Changes to cohort composition, classification rules, and derived variables were documented through versioned datasets and change records. A cohort or dataset passport was used to describe the origin of the data, unit of analysis, cohort-formation rules, level of clinical validation, data limitations, and intended analytical use.
Missing data were not automatically interpreted as absence of the corresponding clinical condition. The amount and pattern of missingness were assessed for relevant variables. Statistical analyses were conducted using the available data for each predefined analytical task. Sensitivity analyses were used where appropriate to assess whether the main findings were affected by alternative cohort definitions, stricter phenotyping rules, or differences in data completeness.
The pandemic and post-pandemic cohorts were analyzed separately and comparatively. The inter-period analysis was intended to assess whether the structure of acute surgical hospitalizations, treatment patterns, and clinical outcomes differed between the specialized pandemic hospital setting and subsequent routine hospital activity. Both broad and more specific cohort definitions were used to evaluate the robustness of the observed differences.
The study also included the development of an organizational and methodological model for conducting research based on real-world data within a medical organization. The model describes the sequence of research activities, distribution of professional roles, clinical validation procedures, data-quality controls, standard operating procedures, dataset documentation, and change management. This component represents a methodological and organizational output of the study and does not constitute an evaluation of the clinical effectiveness of an implemented institutional program.
Because this is a nonrandomized observational study, associations between patient characteristics, treatment strategies, historical periods, and outcomes are interpreted cautiously. Surgical intervention may reflect disease severity, clinical selection, and treatment necessity and is not interpreted as an independently assigned exposure or a proven cause of outcome.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 4 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pandemic-Period Acute Surgical Disease Cohort | – | Procedure: Surgical and Interventional Management of Acute Surgical ConditionsThis cohort includes hospitalizations at the Moscow Multidisciplinary Clinical Center "Kommunarka" from March 1, 2020, to March 1, 2022, in which one or more acute surgical conditions were identified from routine clinical records. The cohort includes hospitalizations with confirmed COVID-19 and hospitalizations without confirmed or probable COVID-19, allowing within-period comparisons by COVID-19 status. No intervention was assigned by the study. Surgical, interventional, or conservative treatment was provided according to routine clinical practice. The cohort was used to assess the structure of acute surgical conditions, in-hospital and postoperative mortality, surgical activity, treatment strategies, and factors associated with adverse outcomes. |
| Post-Pandemic Acute Surgical Disease Cohort | – | Procedure: Surgical and Interventional Management of Acute Surgical ConditionsThis cohort includes emergency hospitalizations at the Moscow Multidisciplinary Clinical Center "Kommunarka" from January 1, 2023, to December 31, 2024, in which one or more acute surgical conditions were identified from routine clinical records. Elective hospitalizations were excluded from the analytical cohort. No intervention was assigned by the study. Surgical, interventional, or conservative treatment was provided according to routine clinical practice. The cohort was used to assess the structure of hospitalizations, in-hospital and postoperative mortality, and surgical activity, and to compare these outcomes with the corresponding pandemic-period cohort using broad and more specific RWD-based cohort definitions. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study cohort was assembled based on data from the Kommunarka Moscow Multidisciplinary Clinical Center (Moscow)-a facility repurposed to treat patients with COVID-19 alongside concurrent acute emergencies across surgical, cardiological, neurological, trauma, and neurosurgical specialties. It comprises medical data regarding the hospitalization and treatment outcomes of patients treated as inpatients during the pandemic period (March 1, 2020, to March 1, 2022) and the post-pandemic period (January 1, 2023, to December 31, 2024). De-identified data were derived from routine medical records and the hospital's medical information system. The dataset reflects real-world clinical practice in the care of patients with COVID-19 and acute surgical conditions, including abdominal, thrombotic, hemorrhagic, infectious-inflammatory, and other surgically significant pathologies.
Key inclusion criteria (6 listed)
- Age 18 years or older.
- Hospitalization at the MMCC "Kommunarka".
- A confirmed diagnosis of COVID-19 (based on current clinical guidelines).
- Presence of one or more any acute surgical diseases (ASD) considered competing with COVID-19 or as a complication of COVID-19/its treatment, as per the discharge summary.
- For specific sub-studies: Patients with acute surgical diseases of the abdominal organs.
Key exclusion criteria (4 listed)
- Patients for whom a diagnosis of COVID-19 was not established according to the discharge summary.
- Patients for whom none of the studied acute surgical diseases were established according to the discharge summary.
- Patients who underwent elective surgeries and developed COVID-19 in the postoperative period.
- Patients operated on in another hospital and transferred with suspected COVID-19 (if not confirmed).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical and Interventional Management of Acute Surgical ConditionsSurgical and interventional procedures performed as part of routine clinical care for acute surgical conditions, including abdominal, thrombotic, hemorrhagic, infectious, and other surgically significant conditions. Procedures included open and laparoscopic surgery, bowel resection, drainage, debridement, hemostatic procedures, angiography, endovascular embolization, and other condition-specific interventions, as clinically indicated. Treatment was not assigned, standardized, or modified by the study protocol. The type and timing of each procedure and the associated in-hospital and postoperative outcomes were obtained from routine medical records and analyzed across clinical subgroups and the pandemic and post-pandemic periods. | Procedure or surgery | Pandemic-Period Acute Surgical Disease Cohort, Post-Pandemic Acute Surgical Disease Cohort |
Primary outcome
In-Hospital Mortality
Time frame: From the moment of admission to the hospital until the date of discharge from the hospital or death (until the end of hospitalization) for the entire study period from 01 march 2020 to 01 march 2022 (from the date of discharge)
The proportion of patients who died during their hospital stay. Assessed in patients with a primary or secondary diagnosis of COVID-19 in combination with competing acute surgical diseases.
4 secondary outcomes
Structure of Morbidity
Time frame: During the entire study period (from 01 march 2020 to 01 march 2022)
Postoperative Mortality
Time frame: From the moment of admission to the hospital until the date of discharge from the hospital or death (until the end of hospitalization) for the entire study period from 01 march 2020 to 01 march 2022 (from the date of discharge)
Surgical Tactics and Outcomes for Specific Conditions
Time frame: From the moment of admission to the hospital until the date of discharge from the hospital or death (until the end of hospitalization) for the entire study period from 01 march 2020 to 01 march 2022 (from the date of discharge)
Surgical Activity
Time frame: At hospital discharge for each hospitalization, with period-level summary at the end of each study period (pandemic: from 01 march 2020 to 01 march 2022 ; post-pandemic: from 01 january 2023 to 01 january 2024).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
- Individual participant dataSharing planned: No. in accordance with national requirements for the security and protection of personal data
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Emergency Surgery, run by Pirogov Russian National Research Medical University at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-Hospital Mortality (time frame: From the moment of admission to the hospital until the date of discharge from the hospital or death (until the end of hospitalization) for the entire study period from 01 march 2020 to 01 march 2022 (from the date of discharge)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.